Go Pro
NASDAQ:NEPH

Nephros Q1 2025 Earnings Report

Nephros logo
$4.55 +0.24 (+5.57%)
As of 08/28/2026 04:00 PM Eastern

Nephros EPS Results

Actual EPS
$0.05
Consensus EPS
-$0.01
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Nephros Revenue Results

Actual Revenue
$4.88 million
Expected Revenue
$3.67 million
Beat/Miss
Beat by +$1.21 million
YoY Revenue Growth
N/A

Nephros Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Nephros' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Nephros Earnings Headlines

Nephros (NEPH) Q2 2026 Earnings Call Transcript
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
Nephros, Inc. (NEPH) Q2 2026 Earnings Call Transcript
See More Nephros Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nephros? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nephros and other key companies, straight to your email.

About Nephros

Nephros (NASDAQ:NEPH), Inc. is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems. Nephros’ Water Purification System (WPS) is engineered to meet stringent U.S. Army and World Health Organization guidelines for field use, delivering potable water from untreated sources. In parallel, the MembraPure™ brand serves pharmaceutical and biotech customers requiring laboratory-grade water for research and manufacturing.

Nephros holds FDA 510(k) clearance for its medical-grade hollow fiber filters, underpinning its role in critical patient care applications. The company distributes products directly to healthcare providers and partners with OEMs and authorized distributors to serve markets across North America and select international territories. Its technology has been adopted by hospitals seeking to safeguard dialysis water and by research institutions requiring ultrapure water for sensitive assays.

Founded in 2005 and headquartered in Kinnelon, New Jersey, Nephros operates under the leadership of President and Chief Executive Officer Hal S. Zarem. The company maintains a focus on product innovation through ongoing research and development efforts, pursuing commercial partnerships and clinical collaborations to expand its footprint in water purification and filtration solutions.

View Nephros Profile